{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:13:21Z","timestamp":1761513201988,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.3816\/cbc.2008.n.055","type":"journal-article","created":{"date-parts":[[2008,10,24]],"date-time":"2008-10-24T21:14:21Z","timestamp":1224882861000},"page":"449-452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunomodulatory Therapy in Multiple Sclerosis and Breast Cancer Risk: A Case Report and Literature Review"],"prefix":"10.3816","volume":"8","author":[{"given":"Rodabe N.","family":"Amaria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Corboy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina A.","family":"Finlayson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William A.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia F.","family":"Borges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"1998","series-title":"McAlpine's Multiples Sclerosis","key":"10.3816\/CBC.2008.n.055_bib1"},{"key":"10.3816\/CBC.2008.n.055_bib2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0733-8619(05)70257-7","article-title":"The epidemiology of multiple sclerosis","volume":"14","author":"Weinshenker","year":"1996","journal-title":"Neurol Clin"},{"key":"10.3816\/CBC.2008.n.055_bib3","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1001\/archneur.1983.04050070036006","article-title":"Epstein-Barr virus infection and antibody synthesis in patients with multiple sclerosis","volume":"40","author":"Bray","year":"1983","journal-title":"Arch Neurol"},{"key":"10.3816\/CBC.2008.n.055_bib4","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/jnnp.64.4.539","article-title":"Altered antibody pattern to Epstein-Barr virus but not other herpes viruses in multiple sclerosis: a population based case-control study from western Norway","volume":"64","author":"Myhr","year":"1998","journal-title":"J Neurol Neurosurg Psych"},{"key":"10.3816\/CBC.2008.n.055_bib5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1600-0404.1998.tb00632.x","article-title":"The implications of Epstein-Barr virus in multiple sclerosis-a review","volume":"97","author":"Munch","year":"1997","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.3816\/CBC.2008.n.055_bib6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/08830180590934976","article-title":"Regulatory T cells in immunologic self-tolerance and autoimmune disease","volume":"24","author":"Sakaguchi","year":"2005","journal-title":"Int Rev Immunol"},{"key":"10.3816\/CBC.2008.n.055_bib7","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1084\/jem.20031579","article-title":"Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis","volume":"199","author":"Viglietta","year":"2004","journal-title":"J Exp Med"},{"key":"10.3816\/CBC.2008.n.055_bib8","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1084\/jem.20032158","article-title":"Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II","volume":"199","author":"Kriegel","year":"2004","journal-title":"J Exp Med"},{"key":"10.3816\/CBC.2008.n.055_bib9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1084\/jem.20040165","article-title":"Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy","volume":"200","author":"Ehrenstein","year":"2004","journal-title":"J Exp Med"},{"key":"10.3816\/CBC.2008.n.055_bib10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2337\/diabetes.54.1.92","article-title":"Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes","volume":"54","author":"Lindley","year":"2005","journal-title":"Diabetes"},{"key":"10.3816\/CBC.2008.n.055_bib11","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1212\/WNL.45.7.1277","article-title":"Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial","volume":"45","author":"The INFB Multiple Sclerosis Study Group","year":"1995","journal-title":"Neurology"},{"key":"10.3816\/CBC.2008.n.055_bib12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group","volume":"39","author":"Jacobs","year":"1996","journal-title":"Ann Neurol"},{"key":"10.3816\/CBC.2008.n.055_bib13","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomized double-blind placebo controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis","volume":"352","author":"PRISMS (Prevention of Relapse and Disability by Interferon \u03b2-1b Subcutaneously in Multiple Sclerosis) Study Group","year":"1998","journal-title":"Lancet"},{"key":"10.3816\/CBC.2008.n.055_bib14","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group","volume":"45","author":"Johnson","year":"1995","journal-title":"Neurology"},{"key":"10.3816\/CBC.2008.n.055_bib15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.autrev.2007.02.003","article-title":"Glatiramer acetate: mechanisms of action in multiple sclerosis","volume":"6","author":"Schrempf","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.3816\/CBC.2008.n.055_bib16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.clim.2007.05.020","article-title":"CD4(+)CD25(+) regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis","volume":"125","author":"Jee","year":"2007","journal-title":"Clin Immunol"},{"key":"10.3816\/CBC.2008.n.055_bib17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.clinthera.2006.04.013","article-title":"Management of worsening multiple sclerosis with mitoxantrone: a review","volume":"28","author":"Fox","year":"2006","journal-title":"Clin Ther"},{"key":"10.3816\/CBC.2008.n.055_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis","volume":"348","author":"Miller","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2008.n.055_bib19","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMc055235","article-title":"Natalizumab and progressive multifocal leukoencephalopathy","volume":"353","author":"Adelman","year":"2005","journal-title":"N Eng J Med"},{"key":"10.3816\/CBC.2008.n.055_bib20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/01.nrl.0000263760.53418.5b","article-title":"Natalizumab (Tysabri) treatment for relapsing multiple sclerosis","volume":"113","author":"Johnson","year":"2007","journal-title":"Neurologist"},{"key":"10.3816\/CBC.2008.n.055_bib22","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.4049\/jimmunol.169.5.2756","article-title":"Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma","volume":"169","author":"Liyanage","year":"2002","journal-title":"J Immunol"},{"key":"10.3816\/CBC.2008.n.055_bib23","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1200\/JCO.2006.05.9584","article-title":"Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse","volume":"24","author":"Bates","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2008.n.055_bib24","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1471-2407-8-57","article-title":"FOXP3+ Tregs and B7-H1+\/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy","volume":"8","author":"Ghebeh","year":"2008","journal-title":"BMC Cancer"},{"key":"10.3816\/CBC.2008.n.055_bib25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1001\/archneur.1971.00490020023002","article-title":"Multiple sclerosis in Rochester, Minn. A 60 year appraisal","volume":"25","author":"Percy","year":"1971","journal-title":"Arch Neurol"},{"key":"10.3816\/CBC.2008.n.055_bib26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/BF00313623","article-title":"Malignant disease among patients with multiple sclerosis","volume":"216","author":"Palo","year":"1977","journal-title":"J Neurol"},{"key":"10.3816\/CBC.2008.n.055_bib27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2990.1978.tb00546.x","article-title":"General disease in 120 necropsy-proven cases of multiple sclerosis","volume":"4","author":"Allen","year":"1978","journal-title":"Neruopathol Appl Neurobiol"},{"key":"10.3816\/CBC.2008.n.055_bib28","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1212\/WNL.41.8.1193","article-title":"Cause of death in patients attending multiple sclerosis clinics","volume":"41","author":"Sadovnick","year":"1991","journal-title":"Neurology"},{"key":"10.3816\/CBC.2008.n.055_bib29","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1600-0404.1991.tb04941.x","article-title":"Cancer incidence following hospitalization for multiple sclerosis in Denmark","volume":"84","author":"Moller","year":"1991","journal-title":"Act Neurol Scand"},{"key":"10.3816\/CBC.2008.n.055_bib30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.65.1.56","article-title":"Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry","volume":"65","author":"Koch-Henriksen","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3816\/CBC.2008.n.055_bib31","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/ijc.21437","article-title":"Cancer risk among patients with multiple sclerosis: a population-based register study","volume":"118","author":"Nielsen","year":"2006","journal-title":"Int J Cancer"},{"key":"10.3816\/CBC.2008.n.055_bib32","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1600-0404.1996.tb00019.x","article-title":"Multiple sclerosis and cancer in Norway. A retrospective cohort study","volume":"93","author":"Midgard","year":"1996","journal-title":"Acta Neurol Scand"},{"key":"10.3816\/CBC.2008.n.055_bib33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10549-004-2229-4","article-title":"Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments","volume":"89","author":"Achiron","year":"2005","journal-title":"Breast Can Res Treat"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911705432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911705432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:09:37Z","timestamp":1761512977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820911705432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S1526820911705432"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2008.n.055","relation":{},"ISSN":["1526-8209"],"issn-type":[{"type":"print","value":"1526-8209"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulatory Therapy in Multiple Sclerosis and Breast Cancer Risk: A Case Report and Literature Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2008.n.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}